Published in J Neurol Neurosurg Psychiatry on December 01, 2005
Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc (2009) 2.34
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep (2007) 2.31
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. J Med Internet Res (2011) 2.19
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Phasic muscle activity in sleep and clinical features of Parkinson disease. Ann Neurol (2010) 1.64
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Treatment of narcolepsy and other hypersomnias of central origin. Sleep (2007) 1.42
Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 1.19
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology (2010) 1.11
A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol (2010) 1.11
Circadian and sleep disorders in Parkinson's disease. Exp Neurol (2012) 1.03
Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.95
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One (2013) 0.94
Treatment of sleep disorders after traumatic brain injury. J Clin Sleep Med (2009) 0.93
Psychiatric issues in cognitive impairment. Mov Disord (2014) 0.91
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry (2010) 0.90
Fatigue in cancer: a review of literature. Indian J Palliat Care (2009) 0.86
Sleep disorders in Parkinson's disease. Neuropsychiatr Dis Treat (2009) 0.84
Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study. Neuropsychiatr Dis Treat (2010) 0.84
Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use. Am J Alzheimers Dis Other Demen (2012) 0.82
Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson's disease. PLoS One (2013) 0.80
A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. Sleep Med Rev (2016) 0.79
Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci (2008) 0.79
Parkinson's disease and sleep/wake disturbances. Parkinsons Dis (2012) 0.78
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders. J Neural Transm (Vienna) (2014) 0.78
Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol (2016) 0.78
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. Transl Neurodegener (2016) 0.77
Diagnosis and management of central hypersomnias. Ther Adv Neurol Disord (2012) 0.77
Daytime sleepiness and Parkinson's disease: the contribution of the multiple sleep latency test. Sleep Disord (2014) 0.76
Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease. Oman Med J (2015) 0.76
Modafinil: Parkinson disease-related somnolence. Hosp Pharm (2014) 0.75
Fibromyalgia-: a review for the psychiatrist. Psychiatry (Edgmont) (2006) 0.75
Management of sleep disorders in Parkinson's disease and multiple system atrophy. Mov Disord (2017) 0.75
Parkinson disease: an update. Neurologist (2004) 0.75
The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. Front Neurol (2017) 0.75
Evaluation and management of the non-motor features of Parkinson's disease. Ther Adv Chronic Dis (2011) 0.75
Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications. P T (2015) 0.75
Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. Front Neurol (2016) 0.75
Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic. Basal Ganglia (2016) 0.75
A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep (1991) 44.17
Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39
Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Evidence for the validity of the Short-form 36 Questionnaire (SF-36) in an elderly population. Age Ageing (1994) 2.79
Fatigue in multiple sclerosis. Arch Neurol (1988) 2.77
Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord (1994) 2.61
Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol (1982) 2.46
Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci (2000) 2.16
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord (2000) 1.78
Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology (2003) 1.59
The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep (1992) 1.54
Disorders of excessive daytime somnolence: polygraphic and clinical data for 100 patients. Sleep (1981) 1.53
Modafinil treatment of pramipexole-associated somnolence. Mov Disord (2000) 1.52
Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology (2001) 1.52
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36
Traffic accidents in commercial long-haul truck drivers: the influence of sleep-disordered breathing and obesity. Sleep (1994) 1.34
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord (2003) 1.34
FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res (2000) 1.27
Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology (2002) 1.25
Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry (2001) 1.21
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep (2002) 1.19
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol (2004) 1.14
Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep (2001) 1.09
Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect (1993) 1.05
Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med (2000) 1.05
Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord (2000) 0.91
Modafinil for the treatment of excessive daytime sleepiness in Parkinson's disease: a case report. Parkinsonism Relat Disord (2001) 0.84
Depressive symptom patterns in patients with Parkinson's disease and other older adults. J Clin Psychol (2001) 0.84
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm (Vienna) (2001) 0.84
Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord (2001) 0.79
Modafinil and pramipexole-associated somnolence. Mov Disord (2001) 0.79
[Sleep-wake complaints in Parkinson's disease]. Rinsho Shinkeigaku (1990) 0.78
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol (1989) 2.91
Essential tremor: clinical correlates in 350 patients. Neurology (1991) 2.89
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
The morbidity and mortality of vermiculite miners and millers exposed to tremolite-actinolite: Part I. Exposure estimates. Am J Ind Med (1987) 2.66
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology (2000) 2.48
Psychogenic myoclonus. Neurology (1993) 2.39
Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 2.38
The impact of depressive symptoms in early Parkinson disease. Neurology (2007) 2.37
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol (1995) 2.21
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg (1997) 2.15
Delayed-onset progressive movement disorders after static brain lesions. Neurology (1996) 1.96
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Hemifacial spasm: clinical findings and treatment. Muscle Nerve (1998) 1.88
Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol (1983) 1.87
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Extrapyramidal involvement in Rett's syndrome. Neurology (1990) 1.74
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 1.68
Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience (2009) 1.67
The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology (1985) 1.65
A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology (2005) 1.63
The alien hand and related signs. J Neurol Neurosurg Psychiatry (1992) 1.62
Orthostatic tremor: an association with essential tremor. Mov Disord (1991) 1.58
Intrathecal baclofen for intractable axial dystonia. Neurology (1991) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Tardive oculogyric crises. Neurology (1989) 1.56
Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol (1986) 1.56
Pallidotomy for generalized dystonia. Mov Disord (1998) 1.54
Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry (1985) 1.52
Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology (2001) 1.52
Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci (2004) 1.50
Bruxism in Huntington's disease. Mov Disord (2000) 1.49
Treatment of palatal myoclonus with sumatriptan. Mov Disord (1996) 1.48
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med (1989) 1.46
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci (1997) 1.43
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord (1996) 1.39
Treating severe bruxism with botulinum toxin. J Am Dent Assoc (2000) 1.38
Blepharospasm associated with brainstem lesions. Neurology (1983) 1.37
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology (2005) 1.34
Association between essential tremor and Parkinson's disease. Ann Neurol (1985) 1.33
Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg (1987) 1.33
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med (1980) 1.28
Relationship of aging to Parkinson's disease. Adv Neurol (1987) 1.28
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology (2004) 1.28
Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology (1988) 1.26
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand (2006) 1.26
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Lower body parkinsonism: evidence for vascular etiology. Mov Disord (1989) 1.24
Low cancer rates among patients with Parkinson's disease. Ann Neurol (1985) 1.24
Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology (1999) 1.23
Movement disorders and AIDS. Neurology (1987) 1.23
Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology (1985) 1.21
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem (1999) 1.21
Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA (1982) 1.19
Stiff-person syndrome: an autoimmune disease. Mov Disord (1991) 1.19
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology (1999) 1.19
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (2007) 1.18
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18
Clinical correlates of vascular parkinsonism. Arch Neurol (1999) 1.18
Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry (1985) 1.17
Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology (2006) 1.17
Criteria for the diagnosis of essential tremor. Neurology (2000) 1.17
Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry (1998) 1.15
Rett syndrome and associated movement disorders. Mov Disord (1990) 1.15
Laterality and symptom association in Parkinson's disease. Arch Neurol (1985) 1.15
Variability and validity of polymorphism association studies in Parkinson's disease. Neurology (2000) 1.14
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology (1997) 1.12
Good communication in psychiatry--a conceptual review. Eur Psychiatry (2011) 1.12
Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology (1998) 1.11
Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol (1982) 1.09
Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol (1999) 1.09
CAG repeat size and clinical presentation in Huntington's disease. Neurology (1994) 1.09
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol (2001) 1.08
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology (2002) 1.08
GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology (2007) 1.07
Essential tremor and PD. Neurology (1993) 1.07
Hearing impairment in essential tremor. Neurology (2003) 1.07
Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord (2011) 1.07
Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord (2000) 1.07
Restless legs syndrome: clinicoetiologic correlates. Neurology (1996) 1.07
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol (1983) 1.06
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett (2000) 1.04
Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord (1996) 1.04
Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol (1984) 1.03
Metoclopramide-induced phantom dyskinesia. Neurology (1985) 1.03
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry (1999) 1.02
Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology (1998) 1.02
Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol (1981) 1.01